Pancreatic ductal adenocarcinoma is an aggressive form of cancer, with low patient survival
rates. Irinotecan, a key chemotherapeutic drug, is activated by carboxylesterase 2, which …

Abstract Background: Serine hydrolases (SHs) are among the largest classes of enzymes in
humans and play crucial role in many pathophysiological processes of cancer. We have …

As the primary enzyme responsible for the activatable conversion of Irinotecan (CPT-11) to
SN-38, carboxylesterase 2 (CES2) is a significant predictive biomarker toward CPT-11 …

Irinotecan-based therapy is a common treatment for pancreatic cancer. To elicit its
anticancer activity, the drug requires first the hydrolysis action of the enzyme human …

Carboxylesterase 2 as a critical hydrolase, current studies are limited to its role in prodrug
metabolism while functional studies found that pancreatic adenocarcinoma (PAAD) is …

Objective Intra-tumoral expression of the serine hydrolase carboxylesterase 2 (CES2)
contributes to the activation of the pro-drug irinotecan in pancreatic ductal adenocarcinoma …

Objective: Intra-tumoral expression of the serine hydrolase carboxylesterase 2 (CES2)
contributes to the activation of the pro-drug irinotecan in pancreatic ductal adenocarcinoma …

PURPOSE The combination chemotherapy of fluorouracil, leucovorin, irinotecan, and
oxaliplatin (FOLFIRINOX) has provided clinically meaningful improvement for pancreatic …

Human carboxylesterase 2 (hCES2) converts anticancer prodrugs, such as irinotecan, into
their active metabolites via phase I drug metabolism. Owing to interindividual variability …

Human carboxylesterase-2 (CE2) is a carboxylesterase that catalyzes the hydrolysis of
endogenous and exogenous substrates. Abnormal CE2 levels are associated with various …